`______________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`______________
`
`PFIZER INC.,
`Petitioner,
`
`v.
`
`NOVO NORDISK A/S,
`Patent Owner.
`______________
`
`Case IPR2020-01252
`Patent 8,114,833
`______________
`
`PATENT OWNER’S MANDATORY NOTICE INFORMATION
`UNDER 37 C.F.R. § 42.8
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Pursuant to 37 C.F.R. § 42.8(a)(2), Patent Owner, Novo Nordisk A/S (“Novo
`
`IPR2020-01252
`Patent 8,114,833
`
`Nordisk”), hereby files its Mandatory Notices:
`
`I.
`
`Real Party-in-Interest (§ 42.8(b)(1))
`
`The following real parties-in-interest are identified: Novo Nordisk A/S, Novo
`
`Nordisk Inc., Novo Holdings A/S, and Novo Nordisk Foundation.
`
`II. Related Matters (§ 42.8(b)(2))
`
`Patent Owner is aware of the following proceeding before the USPTO
`
`involving U.S. Patent No. 8,114,833: Mylan Institutional LLC. v. Novo Nordisk A/S,
`
`No. IPR2020-00324. IPR2020-00324 was instituted and is currently pending.
`
` Patent Owner is also aware of the following district court litigations
`
`involving U.S. Patent No. 8,114,833: Novo Nordisk Inc. and Novo Nordisk A/S v.
`
`Mylan Institutional LLC, No. 19-cv-1551-CFC (D. Del.); Novo Nordisk Inc. and
`
`Novo Nordisk A/S v. Mylan Institutional LLC, No. 19-cv-164 (N.D. W. Va.); Novo
`
`Nordisk Inc. and Novo Nordisk A/S v. Sandoz Inc., No. 20-cv-747-CFC (D. Del.);
`
`Novo Nordisk Inc. and Novo Nordisk A/S v. Sandoz Inc., 20-cv-6842-RMB-AMD
`
`(D.N.J.). Case Nos. 19-cv-1551-CFC and 20-cv-747-CFC are currently pending.
`
`Case Nos. 19-cv-164 and 20-cv-6842-RMB-AMD have been voluntarily dismissed.
`
`U.S. Patent Application No. 16/260,204, which is pending and was filed on
`
`January 29, 2019, and U.S. Patent Application No. 16/910,945, which is pending
`
`
`
`1
`
`
`
`
`
`IPR2020-01252
`Patent 8,114,833
`
`and was filed on June 24, 2020, both claim the benefit of U.S. Application No.
`
`11/435,977, which is the application that issued as U.S. Patent No. 8,114,833.
`
`III. Counsel and Service Information (§§ 42.8(b)(3) and (4))
`
`Patent Owner identifies its lead and backup counsel as shown below:
`
`Lead Counsel
`Jeffrey J. Oelke
`FENWICK & WEST LLP
`902 Broadway, Suite 14
`New York, NY 10010
`(212) 430-2600 (tel)
`(650) 938-5200 (fax)
`joelke@fenwick.com
`USPTO Reg. No. 37,409
`
`Backup Counsel
`Ryan P. Johnson
`(pro hac vice to be sought)
`FENWICK & WEST LLP
`902 Broadway, Suite 14
`New York, NY 10010
`(212) 430-2600 (tel)
`(650) 938-5200 (fax)
`ryan.johnson@fenwick.com
`
`Laura T. Moran
`(pro hac vice to be sought)
`FENWICK & WEST LLP
`902 Broadway, Suite 14
`New York, NY 10010
`(212) 430-2600 (tel)
`(650) 938-5200 (fax)
`laura.moran@fenwick.com
`
`
`
`
`Please address all correspondence to the lead and backup counsel at the above
`
`addresses and to Novo833IPR@fenwick.com. Patent Owner consents to electronic
`
`service to the e-mail addresses above for lead and backup counsel and to
`
`Novo833IPR@fenwick.com.
`
`IV. Patent Owner Preliminary Response
`
`Patent Owner reserves the right to file a preliminary response at a later date.
`
`
`
`2
`
`
`
`
`
`IPR2020-01252
`Patent 8,114,833
`
`V.
`
`Patent Owner Power of Attorney
`
`A Power of Attorney to transact all business in the United States Patent and
`
`Trademark Office in connection with above-referenced Inter Partes Review from
`
`Patent Owner Novo Nordisk A/S to the above-designated counsel at Fenwick &
`
`West LLP is being filed concurrently with these Mandatory Notices.
`
`Dated: August 12, 2020
`
`
`
`Respectfully submitted,
`
`
`
`
`/Jeffrey J. Oelke/
`Jeffrey J. Oelke (Reg. No. 37,409)
`FENWICK & WEST LLP
`902 Broadway, Suite 14
`New York, NY 10010
`(212) 430-2600 (tel)
`(650) 938-5200 (fax)
`joelke@fenwick.com
`
`Counsel for Novo Nordisk A/S
`
`
`
`3
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that a copy of the foregoing Patent Owner’s
`
`Mandatory Notice Information Under 37 C.F.R. § 42.8 was served on August 12,
`
`2020, by filing this document through the Patent Trial and Appeal Board End to End
`
`System, as well as delivering a copy via electronic mail upon the following attorneys
`
`of record for the Petitioner:
`
`Jovial Wong
`Charles B. Klein
`Sharon Lin
`jwong@winston.com
`cklein@winston.com
`slin@winston.com
`PfizerIPRs@winston.com
`
`
`Date: August 12, 2020
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`
`
`/ Jeffrey J. Oelke/
`Jeffrey J. Oelke (Reg. No. 37,409)
`
`Counsel for Novo Nordisk A/S
`
`